CompletedNot Applicable

High Density Mapping in Brugada Syndrome

Belgium15 participantsStarted 2018-04-01

Plain-language summary

The current study has the following objectives: 1. To characterize the changes in amplitude and duration of epicardial right ventricular outflow tract electrograms captured through a multipolar mapping catheter in patients with Brugada syndrome before and after an ajmaline challenge. 2. To investigate the relationship between the above cited invasive electrophysiological findings and non invasive ECG imaging (ECGI) of the epicardial layer of the right ventricular outflow tract (RVOT) of patients affected by Brugada syndrome and undergoing substrate thoracoscopic catheter ablation.

Who can participate

Age range15 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. high density epicardial EAM performed with the multipolar mapping catheter Advisor™ HD-Grid Mapping Catheter, (Abbott Labs, Abbott Park, IL, USA) in association with the EnSite Precision™ Cardiac Mapping System, (Abbott Labs, Abbott Park, IL, USA);
✓. epicardial EAM performed before and after ajmaline infusion at standard protocol (1 mg/kg in 5 minutes);
✓. ECGI activation map performed before and after ajmaline and concomitant with invasive EAM acquisition.

Exclusion criteria

✕. Spontaneous BrS type I pattern ECG during EAM acquisition. Patients were included if they had a history of spontaneous BrS type I;
✕. other diagnosis different from BrS syndrome or overlap syndrome diagnosis by means of genetic analysis, transthoracic echocardiography, computed tomography (CT) or magnetic resonance imaging;
✕. use of a different mapping catheter or mapping system;
✕. history of previous BrS substrate ablation.

What they're measuring

HD-grid electrograms

Timeframe: During ablation

Trial details

NCT IDNCT06567639

SponsorUniversitair Ziekenhuis Brussel

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-03-31

View on ClinicalTrials.gov More Brugada Syndrome trials